Baxter launches access programme for GammaGard

Baxter International has announced the launch of its “innovative” Gardian initiative for the provision of continued access to medication for patients receiving Gammagard Liquid and Gammagard S/D [Immune Globulin Intravenous (Human)] (IGIV).

The programme seeks to give doctors and patients ongoing access to GammaGard in spite of changes to providers and sites of care that can on occasion inhibit access to preferred IGIV therapy.

Baxter notes that this scheme is an extension to other initiatives from the firm, including GammAsist, the low IgA/brand intolerance programme and GammaGard Liquid and GammaGard S/D portability.

IGIV treatments are used to replace broad-spectrum immunoglobulins in patients exhibiting primary immunodeficiency.

Fred Modell, co-founder of the Jeffrey Modell Foundation, said: “Baxter has been a pioneer in advancing the science of IGIV and its intent to establish a program that maintains continuity in IGIV therapy at the patient level is an important innovation in the industry.”

He added that this programme will be embraced by primary immunodeficiency patients requiring ongoing access to GammaGard Liquid and GammaGard S/D.

In January 2006, the European Medicines Agency granted marketing authorisation for Baxter Healthcare’s IVIG Kiovig as a replacement therapy in primary immunodeficiency disorders, chronic lymphocytic leukaemia, myeloma and other conditions.